mesalamine has been researched along with Innate Inflammatory Response in 68 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the role of 1-glutamine, short chain fatty acid, prednisolone, and mesalazine (5-aminosalicylic acid) enemas on mucosal damage and inflammation in experimental colitis." | 7.70 | L-glutamine enemas attenuate mucosal injury in experimental colitis. ( Bayer, A; Gür, ES; Kaya, E; Ozgüç, H; Tokyay, R, 1999) |
| "Allicin has anti-inflammatory, antioxidative and proapoptotic properties." | 5.42 | Allicin alleviates inflammation of trinitrobenzenesulfonic acid-induced rats and suppresses P38 and JNK pathways in Caco-2 cells. ( Guo, Y; Lei, S; Li, C; Lun, W; Ma, J; Zhao, X; Zhi, F, 2015) |
| "Mesalamine suppositories have been used widely for the treatment of distal ulcerative colitis and considered to be safer than systemic administration for its limited systemic absorption." | 5.40 | Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity. ( Ding, H; Hu, J; Hu, XY; Liu, XC; Mei, Q; Xu, JM, 2014) |
| "The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis." | 5.19 | The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. ( Abdel-Mohsen, M; Albright, R; Cohen, M; Deeks, SG; Dunham, RM; Gorelick, R; Hsue, PY; Huang, Y; Hunt, PW; Liegler, T; Lifson, J; Martin, JN; McCune, JM; Piatak, M; Somsouk, M; Wu, Y, 2014) |
| "Topical mesalamine appears well tolerated and effective in treating patients with cuffitis, with improvement in symptom as well as endoscopic and histologic inflammation." | 5.11 | Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis. ( Achkar, JP; Bambrick, ML; Bast, J; Bennett, AE; Brzezinski, A; Fazio, VW; Lashner, BA; Remzi, FH; Shen, B, 2004) |
| "), with that of 5-aminosalicylic acid (5-ASA), a first-line drug in IBD, in a 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis rat model." | 3.85 | Comparison of anti-inflammatory activities of an anthocyanin-rich fraction from Portuguese blueberries (Vaccinium corymbosum L.) and 5-aminosalicylic acid in a TNBS-induced colitis rat model. ( Almeida, LM; Dinis, TC; Figueiredo, I; Freitas, V; Pereira, R; Pereira, SR, 2017) |
| "To investigate the therapeutic and immunoregulatory effects of 1,25-dihydroxyvitamin D (1,25(OH)D3) on 2,4,6-trinitrobenzenesulfonic acid (TNBS) -induced colitis in rats." | 3.81 | 1,25-hydroxyvitamin D relieves colitis in rats via down-regulation of toll-like receptor 9 expression. ( Dai, ZH; Lv, H; Qian, JM; Tan, B; Wang, O; Yang, H, 2015) |
| "Inflammation-targeted treatment of patients with UC is effective and costs less than continuous treatment of all patients with mesalamine, the current standard of care." | 3.78 | Cost utility of inflammation-targeted therapy for patients with ulcerative colitis. ( Higgins, PD; Saini, SD; Waljee, AK, 2012) |
| "The aim of this study was to investigate the role of 1-glutamine, short chain fatty acid, prednisolone, and mesalazine (5-aminosalicylic acid) enemas on mucosal damage and inflammation in experimental colitis." | 3.70 | L-glutamine enemas attenuate mucosal injury in experimental colitis. ( Bayer, A; Gür, ES; Kaya, E; Ozgüç, H; Tokyay, R, 1999) |
| "The risk of colorectal cancer after 20 years of disease duration is 4." | 3.01 | Ulcerative Colitis in Adults: A Review. ( Gros, B; Kaplan, GG, 2023) |
| "Mesalazine is a key drug in the treatment of ulcerative colitis (UC)." | 2.80 | Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study. ( Buurman, DJ; De Monchy, JG; Dijkstra, G; Kleibeuker, JH; Schellekens, RC; van der Waaij, LA, 2015) |
| "In contrast to other agents used in the treatment of ulcerative colitis, 5-ASA does not have any known anti-inflammatory effect on other organs or other colonic inflammatory diseases like diverticulitis." | 2.52 | 5-Aminosalicylic acid, a specific drug for ulcerative colitis. ( Hauso, Ø; Martinsen, TC; Waldum, H, 2015) |
| "Because intestinal inflammation affects the gut microbiota and 5-ASA can change the severity of inflammation, assessing the impact of inflammation and 5-ASA on the gut microbiota is not feasible in a clinical study of patients with UC." | 1.91 | 5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis. ( Akimoto, Y; Hibi, N; Hibi, T; Hisamatsu, T; Kobayashi, T; Kuronuma, S; Lee, STM; Matsuura, M; Miyoshi, J; Nishinarita, Y; Oguri, N; Takeuchi, O; Wada, H, 2023) |
| "Ulcerative colitis is a condition of chronic inflammation affecting the large intestine." | 1.72 | Use of Novel Biological Agent in Severe Ulcerative Colitis with Poor Response to Initial Therapy: A Case Report. ( Basnet, BK; Bhandari, A, 2022) |
| "Post-treatment inflammation distribution can change over time." | 1.51 | Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activity and therapeutic response. ( Chang, CW; Chen, MJ; Hsu, TC; Lin, WC; Wang, HY, 2019) |
| "Allicin has anti-inflammatory, antioxidative and proapoptotic properties." | 1.42 | Allicin alleviates inflammation of trinitrobenzenesulfonic acid-induced rats and suppresses P38 and JNK pathways in Caco-2 cells. ( Guo, Y; Lei, S; Li, C; Lun, W; Ma, J; Zhao, X; Zhi, F, 2015) |
| "Mesalamine suppositories have been used widely for the treatment of distal ulcerative colitis and considered to be safer than systemic administration for its limited systemic absorption." | 1.40 | Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity. ( Ding, H; Hu, J; Hu, XY; Liu, XC; Mei, Q; Xu, JM, 2014) |
| "Colitis was induced by intrarectal injection of TNBS while control rats received the vehicle." | 1.39 | Adjunct therapy of n-3 fatty acids to 5-ASA ameliorates inflammatory score and decreases NF-κB in rats with TNBS-induced colitis. ( Aziz, M; Bole-Feysot, C; Charpentier, C; Déchelotte, P; Guérin, C; Marion-Letellier, R; Mbodji, K; Querec, C; Savoye, G, 2013) |
| "Subclinical inflammation in ulcerative colitis (UC) can predispose to relapses and biomarkers can detect mucosal inflammation." | 1.38 | Evaluation of fecal myeloperoxidase as a biomarker of disease activity and severity in ulcerative colitis. ( Dutta, U; Hussain, S; Kochhar, R; Masoodi, I; Prasad, KK; Singh, K; Vaiphei, K; Vaishnavi, C, 2012) |
| "Pre-treatment with prednisolone decreased the cell attracting effect of ICAM-1 in a dose-dependent manner to 72% of the basal migration (P<0." | 1.31 | Chemotactic properties of ICAM-1 and PECAM-1 on neutrophil granulocytes in ulcerative colitis: effects of prednisolone and mesalazine. ( Nielsen, OH; Vainer, B, 2000) |
| "According to Truelove and Witts, ulcerative colitis has been rated only by clinical classification without taking into account morphological alterations, and so far (in contrast to Crohn's disease) no activity index has been available for clinical studies." | 1.27 | [Ulcerative colitis. Activity index for the clinical and histological classification of inflammatory activity]. ( Kraus, B; Maier, K; von Gaisberg, U, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (7.35) | 18.7374 |
| 1990's | 5 (7.35) | 18.2507 |
| 2000's | 6 (8.82) | 29.6817 |
| 2010's | 38 (55.88) | 24.3611 |
| 2020's | 14 (20.59) | 2.80 |
| Authors | Studies |
|---|---|
| Wakai, M | 1 |
| Hayashi, R | 1 |
| Ueno, Y | 1 |
| Onishi, K | 1 |
| Takasago, T | 1 |
| Uchida, T | 1 |
| Takigawa, H | 1 |
| Yuge, R | 1 |
| Urabe, Y | 1 |
| Oka, S | 1 |
| Kitadai, Y | 1 |
| Tanaka, S | 1 |
| Xia, S | 1 |
| Chen, L | 1 |
| Li, Z | 1 |
| Li, Y | 2 |
| Zhou, Y | 1 |
| Sun, S | 1 |
| Su, Y | 1 |
| Xu, X | 1 |
| Shao, J | 1 |
| Zhang, Z | 1 |
| Kong, D | 1 |
| Zhang, F | 1 |
| Zheng, S | 1 |
| Liu, Y | 1 |
| Sun, Y | 2 |
| Wang, X | 2 |
| Wang, D | 1 |
| Zeng, L | 1 |
| Lu, Q | 1 |
| Chung, KS | 1 |
| Park, SE | 1 |
| Lee, JH | 1 |
| Kim, SY | 1 |
| Han, HS | 1 |
| Lee, YS | 1 |
| Jung, SH | 1 |
| Jang, E | 1 |
| Lee, S | 2 |
| Lee, KT | 1 |
| Pituch-Zdanowska, A | 1 |
| Dembiński, Ł | 1 |
| Banaszkiewicz, A | 1 |
| Bhandari, A | 1 |
| Basnet, BK | 1 |
| Wei, M | 1 |
| Liu, D | 1 |
| Xie, H | 1 |
| Du, L | 1 |
| Jin, Y | 1 |
| Wada, H | 1 |
| Miyoshi, J | 1 |
| Kuronuma, S | 1 |
| Nishinarita, Y | 1 |
| Oguri, N | 1 |
| Hibi, N | 1 |
| Takeuchi, O | 1 |
| Akimoto, Y | 1 |
| Lee, STM | 1 |
| Matsuura, M | 1 |
| Kobayashi, T | 1 |
| Hibi, T | 2 |
| Hisamatsu, T | 1 |
| Gros, B | 1 |
| Kaplan, GG | 1 |
| Do, HJ | 1 |
| Kim, YS | 1 |
| Oh, TW | 1 |
| Liang, J | 1 |
| Li, H | 1 |
| Chen, J | 1 |
| He, L | 1 |
| Du, X | 1 |
| Zhou, L | 1 |
| Xiong, Q | 1 |
| Lai, X | 1 |
| Yang, Y | 1 |
| Huang, S | 1 |
| Hou, S | 1 |
| Ma, C | 1 |
| Sandborn, WJ | 1 |
| D'Haens, GR | 1 |
| Zou, G | 1 |
| Stitt, LW | 1 |
| Singh, S | 1 |
| Ananthakrishnan, AN | 1 |
| Dulai, PS | 1 |
| Khanna, R | 1 |
| Jairath, V | 1 |
| Feagan, BG | 1 |
| Iwamoto, M | 1 |
| Kato, K | 1 |
| Moriyama, M | 1 |
| Yamaguchi, K | 1 |
| Takahashi, S | 1 |
| El-Baz, AM | 1 |
| Khodir, AE | 1 |
| Adel El-Sokkary, MM | 1 |
| Shata, A | 1 |
| Cevallos, SA | 1 |
| Lee, JY | 1 |
| Velazquez, EM | 1 |
| Foegeding, NJ | 1 |
| Shelton, CD | 1 |
| Tiffany, CR | 1 |
| Parry, BH | 1 |
| Stull-Lane, AR | 1 |
| Olsan, EE | 1 |
| Savage, HP | 1 |
| Nguyen, H | 1 |
| Ghanaat, SS | 1 |
| Byndloss, AJ | 1 |
| Agu, IO | 1 |
| Tsolis, RM | 1 |
| Byndloss, MX | 1 |
| Bäumler, AJ | 1 |
| Pereira, SR | 1 |
| Pereira, R | 1 |
| Figueiredo, I | 1 |
| Freitas, V | 1 |
| Dinis, TC | 2 |
| Almeida, LM | 2 |
| Kang, S | 1 |
| Kim, W | 1 |
| Jeong, S | 1 |
| Lee, Y | 1 |
| Nam, J | 1 |
| Jung, Y | 1 |
| Wang, Z | 1 |
| Koonen, D | 1 |
| Hofker, M | 1 |
| Bao, Z | 1 |
| Angelidou, I | 1 |
| Chrysanthopoulou, A | 1 |
| Mitsios, A | 1 |
| Arelaki, S | 1 |
| Arampatzioglou, A | 1 |
| Kambas, K | 1 |
| Ritis, D | 1 |
| Tsironidou, V | 1 |
| Moschos, I | 1 |
| Dalla, V | 1 |
| Stakos, D | 1 |
| Kouklakis, G | 1 |
| Mitroulis, I | 1 |
| Ritis, K | 1 |
| Skendros, P | 1 |
| Khare, V | 2 |
| Krnjic, A | 1 |
| Frick, A | 1 |
| Gmainer, C | 1 |
| Asboth, M | 1 |
| Jimenez, K | 1 |
| Lang, M | 2 |
| Baumgartner, M | 1 |
| Evstatiev, R | 2 |
| Gasche, C | 2 |
| Lin, WC | 1 |
| Chang, CW | 1 |
| Chen, MJ | 1 |
| Hsu, TC | 1 |
| Wang, HY | 1 |
| Koláček, M | 1 |
| Muchová, J | 1 |
| Dvořáková, M | 1 |
| Paduchová, Z | 1 |
| Žitňanová, I | 1 |
| Čierna, I | 1 |
| Országhová, Z | 1 |
| Székyová, D | 1 |
| Jajcaiová-Zedníčková, N | 1 |
| Kovács, L | 1 |
| Ďuračková, Z | 1 |
| Watanabe, M | 1 |
| Nishino, H | 1 |
| Sameshima, Y | 1 |
| Ota, A | 1 |
| Nakamura, S | 1 |
| Nieminen, U | 1 |
| Jussila, A | 1 |
| Nordling, S | 1 |
| Mustonen, H | 1 |
| Färkkilä, MA | 1 |
| Serra, D | 1 |
| Paixão, J | 1 |
| Nunes, C | 1 |
| Wolff, S | 1 |
| Terheggen, G | 1 |
| Mueller, R | 1 |
| Greinwald, R | 1 |
| Franklin, J | 1 |
| Kruis, W | 1 |
| MacFie, TS | 1 |
| Poulsom, R | 1 |
| Parker, A | 1 |
| Warnes, G | 1 |
| Boitsova, T | 1 |
| Nijhuis, A | 1 |
| Suraweera, N | 1 |
| Poehlmann, A | 1 |
| Szary, J | 1 |
| Feakins, R | 1 |
| Jeffery, R | 1 |
| Harper, RW | 1 |
| Jubb, AM | 1 |
| Lindsay, JO | 1 |
| Silver, A | 1 |
| Ding, H | 1 |
| Liu, XC | 1 |
| Mei, Q | 1 |
| Xu, JM | 1 |
| Hu, XY | 1 |
| Hu, J | 1 |
| Behnen, M | 1 |
| Leschczyk, C | 1 |
| Möller, S | 1 |
| Batel, T | 1 |
| Klinger, M | 1 |
| Solbach, W | 1 |
| Laskay, T | 1 |
| Raju, KR | 1 |
| Kumar, MN | 1 |
| Gupta, S | 1 |
| Naga, ST | 1 |
| Shankar, JK | 1 |
| Murthy, V | 1 |
| Madhunapanthula, SR | 1 |
| Mulukutla, S | 1 |
| Ambhore, NS | 1 |
| Tummala, S | 1 |
| Vishnuvarthan, VJ | 1 |
| Azam, A | 1 |
| Elango, K | 1 |
| Yamada, S | 1 |
| Koyama, T | 1 |
| Noguchi, H | 1 |
| Ueda, Y | 1 |
| Kitsuyama, R | 1 |
| Shimizu, H | 1 |
| Tanimoto, A | 1 |
| Wang, KY | 1 |
| Nawata, A | 1 |
| Nakayama, T | 1 |
| Sasaguri, Y | 1 |
| Satoh, T | 1 |
| Lu, YL | 1 |
| Shen, H | 1 |
| Yao, HF | 1 |
| Yang, X | 1 |
| Somsouk, M | 1 |
| Dunham, RM | 1 |
| Cohen, M | 1 |
| Albright, R | 1 |
| Abdel-Mohsen, M | 1 |
| Liegler, T | 1 |
| Lifson, J | 1 |
| Piatak, M | 1 |
| Gorelick, R | 1 |
| Huang, Y | 1 |
| Wu, Y | 1 |
| Hsue, PY | 1 |
| Martin, JN | 1 |
| Deeks, SG | 1 |
| McCune, JM | 1 |
| Hunt, PW | 1 |
| Buurman, DJ | 1 |
| De Monchy, JG | 1 |
| Schellekens, RC | 1 |
| van der Waaij, LA | 1 |
| Kleibeuker, JH | 1 |
| Dijkstra, G | 1 |
| Li, C | 1 |
| Lun, W | 1 |
| Zhao, X | 1 |
| Lei, S | 1 |
| Guo, Y | 1 |
| Ma, J | 1 |
| Zhi, F | 1 |
| Hauso, Ø | 1 |
| Martinsen, TC | 1 |
| Waldum, H | 1 |
| Tang, Y | 1 |
| Chen, Y | 1 |
| Song, G | 1 |
| Shi, L | 1 |
| Dammann, K | 1 |
| Harpain, F | 1 |
| Kurtovic, A | 1 |
| Mesteri, I | 1 |
| Scaioli, E | 1 |
| Colecchia, A | 1 |
| Marasco, G | 1 |
| Schiumerini, R | 1 |
| Festi, D | 1 |
| Dai, ZH | 1 |
| Tan, B | 1 |
| Yang, H | 1 |
| Wang, O | 1 |
| Qian, JM | 1 |
| Lv, H | 1 |
| Wiese, DM | 1 |
| Horst, SN | 1 |
| Brown, CT | 1 |
| Allaman, MM | 1 |
| Hodges, ME | 1 |
| Slaughter, JC | 1 |
| Druce, JP | 1 |
| Beaulieu, DB | 1 |
| Schwartz, DA | 1 |
| Wilson, KT | 1 |
| Coburn, LA | 1 |
| Simon, H | 1 |
| Fischer, T | 1 |
| Almási, A | 1 |
| Fischer, E | 1 |
| Jegadeesan, R | 1 |
| Navaneethan, U | 1 |
| Gutierrez, NG | 1 |
| Venkatesh, PG | 1 |
| Hammel, JP | 1 |
| Sanaka, MR | 1 |
| Shen, B | 2 |
| Qu, T | 1 |
| Wang, E | 1 |
| Jin, B | 1 |
| Li, W | 1 |
| Liu, R | 1 |
| Zhao, ZB | 1 |
| Zheng, L | 1 |
| Zhang, YL | 1 |
| Dai, YC | 1 |
| Chen, X | 1 |
| Chen, DL | 1 |
| Dai, YT | 1 |
| Tang, ZP | 1 |
| Rodríguez-Reyna, TS | 1 |
| Martínez-Reyes, C | 1 |
| Yamamoto-Furusho, JK | 1 |
| Tomasello, G | 1 |
| Rodolico, V | 1 |
| Zerilli, M | 1 |
| Martorana, A | 1 |
| Bucchieri, F | 1 |
| Pitruzzella, A | 1 |
| Marino Gammazza, A | 1 |
| David, S | 1 |
| Rappa, F | 1 |
| Zummo, G | 1 |
| Damiani, P | 1 |
| Accomando, S | 1 |
| Rizzo, M | 1 |
| de Macario, EC | 1 |
| Macario, AJ | 1 |
| Cappello, F | 1 |
| Spinelli, A | 1 |
| Sacchi, M | 1 |
| Fiorino, G | 1 |
| Danese, S | 1 |
| Montorsi, M | 1 |
| Masoodi, I | 1 |
| Kochhar, R | 1 |
| Dutta, U | 1 |
| Vaishnavi, C | 1 |
| Prasad, KK | 1 |
| Vaiphei, K | 1 |
| Hussain, S | 1 |
| Singh, K | 1 |
| Bautzová, T | 1 |
| Rabišková, M | 1 |
| Béduneau, A | 1 |
| Pellequer, Y | 1 |
| Lamprecht, A | 1 |
| Saini, SD | 1 |
| Waljee, AK | 1 |
| Higgins, PD | 1 |
| Tursi, A | 2 |
| Elisei, W | 1 |
| Brandimarte, G | 1 |
| Giorgetti, GM | 1 |
| Inchingolo, CD | 1 |
| Nenna, R | 1 |
| Picchio, M | 1 |
| Giorgio, F | 1 |
| Ierardi, E | 1 |
| Mbodji, K | 1 |
| Charpentier, C | 1 |
| Guérin, C | 1 |
| Querec, C | 1 |
| Bole-Feysot, C | 1 |
| Aziz, M | 1 |
| Savoye, G | 1 |
| Déchelotte, P | 1 |
| Marion-Letellier, R | 1 |
| Lashner, BA | 1 |
| Bennett, AE | 1 |
| Remzi, FH | 1 |
| Brzezinski, A | 1 |
| Achkar, JP | 1 |
| Bast, J | 1 |
| Bambrick, ML | 1 |
| Fazio, VW | 1 |
| Joshi, R | 1 |
| Kumar, S | 1 |
| Unnikrishnan, M | 1 |
| Mukherjee, T | 1 |
| Linard, C | 1 |
| Grémy, O | 1 |
| Benderitter, M | 1 |
| Verspaget, HW | 1 |
| Kaya, E | 1 |
| Gür, ES | 1 |
| Ozgüç, H | 1 |
| Bayer, A | 1 |
| Tokyay, R | 1 |
| Vainer, B | 1 |
| Nielsen, OH | 1 |
| Tamai, H | 1 |
| Levin, S | 1 |
| Gaginella, TS | 1 |
| Grisham, MB | 1 |
| Ware, K | 1 |
| Gilleland, HE | 1 |
| Gilleland, LB | 1 |
| Abell, CL | 1 |
| Yamada, T | 1 |
| Mayberry, JF | 1 |
| Balfour, TW | 1 |
| Long, RG | 1 |
| Donowitz, M | 1 |
| Gendre, JP | 1 |
| Maier, K | 1 |
| von Gaisberg, U | 1 |
| Kraus, B | 1 |
| Loizeau, E | 1 |
| Klotz, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Active-Controlled, Double-Blind and Open Label Extensions Study to Evaluate the Efficacy, Long-Term Safety and Tolerability of TP05 3.2g/Day for the Treatment of Active Ulcerative Colitis[NCT01903252] | Phase 3 | 817 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| Markers of Oxidative Stress in Inflammatory Bowel Disease in Children and Adults: Risk Factors and Implications for a Dietetic Approach[NCT04513015] | 40 participants (Anticipated) | Interventional | 2019-12-15 | Recruiting | |||
| Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy[NCT01295515] | Phase 1/Phase 2 | 7 participants (Actual) | Interventional | 2011-02-11 | Completed | ||
| Mesalamine to Reduce T Cell Activation in HIV Infection[NCT01090102] | Phase 4 | 33 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis[NCT00583531] | Phase 2 | 2 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Lack of enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Between-Group Difference of Endoscopic Score, Change from Baseline. The changes from baseline to week 8 values in sigmoidoscopic (mucosal) appearance scores will be compared between the two treatment groups. A value of 0 in the endoscopic score means normal or inactive disease and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success. (NCT01903252)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| TP05 (Mesalazine) | 0.5 |
| Asacol (Mesalazine) | 0.6 |
"Between-Group Difference of Mayo Score, Change from Baseline The changes from baseline to week 8 values in Mayo scores are compared between the two treatment groups.~The Mayo scoring system is a well-established tool for assessing UC disease activity. The Mayo score is the sum of 4 component sub-scores, each scored on a scale ranging from 0 representing no pathology to 3 for severe disease. The 4 component sub-scores consist of, 1) stool frequency, 2) rectal bleeding, 3) flexible sigmoidoscopy scores, and 4) physician's global assessment. A Mayo score of 0 indicates no pathology and a score of 12, severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Mayo score from baseline when patients experienced acute disease, indicates improvement and treatment success." (NCT01903252)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| TP05 (Mesalazine) | 3.1 |
| Asacol (Mesalazine) | 3.2 |
Between-Group Difference of Partial Mayo Score, Change from Baseline to Week 8 The Partial Mayo Score is the sum of the component sub-scores, 1) stool frequency, 2) rectal bleeding and 3) physician's global assessment. A partial Mayo Score of 0 indicates no disease and a maximum score of 9 indicates severe symptoms. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Partial Mayo Score from Baseline where patients experienced acute disease, indicates improvement and treatment success. (NCT01903252)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| TP05 (Mesalazine) | 2.5 |
| Asacol (Mesalazine) | 2.5 |
"Between-Group Difference of Physician Global Assessment Score, Change from Baseline.~The changes from baseline to week 8 values in the Physician Global Assessment score will be compared between the two treatment groups. A value of 0 means no pathology and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success." (NCT01903252)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| TP05 (Mesalazine) | 0.6 |
| Asacol (Mesalazine) | 0.7 |
Between-Group Difference of Rectal Bleeding Score, Change from Baseline The changes from baseline to week 8 values in rectal bleeding scores will be compared between the two treatment groups. A value of 0 indicates no rectal bleeding, a value of 3 indicates only blood is passing. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference at week 8 compared to baseline is indicative of treatment success. (NCT01903252)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| TP05 (Mesalazine) | 0.9 |
| Asacol (Mesalazine) | 1.0 |
Between-Group Difference of Stool Frequency Score, Change from Baseline The changes from baseline to week 8 values in stool frequency will be compared between the two treatment groups. Values for stool frequency range between 0 and 3. A value of 0 indicates normal stool frequency, a value of 3 indicates 5 or more stools than normal. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between week 8 values and baselines indicates treatment success. (NCT01903252)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| TP05 (Mesalazine) | 0.9 |
| Asacol (Mesalazine) | 0.9 |
Mayo Score of <= 2 points with no individual sub-score > 1 (NCT01903252)
Timeframe: Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 87 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 95 |
Clinical and Endoscopic Response was defined as a decrease in the Mayo score of ≥3 points from baseline and a reduction of ≥ 30% from baseline with either an accompanying decrease in the rectal bleeding sub-score of at least 1 point or an absolute rectal bleeding sub-score of 0 or 1 at the Week 8 visit. If a subject withdrew from the study prior to Week 8 or their response status was not evaluable due to incomplete and/or invalid data, the subject was considered a non-responder. (NCT01903252)
Timeframe: Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 221 |
| Asacol (Mesalazine) | 236 |
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS) (NCT01903252)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 93 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 113 |
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS) (NCT01903252)
Timeframe: Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 92 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 110 |
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS) (NCT01903252)
Timeframe: Week 8 and week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 66 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 80 |
A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0. (NCT01903252)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 223 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 233 |
A decrease in the Partial Mayo Score of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0. (NCT01903252)
Timeframe: Week 8 and Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 216 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 230 |
Endoscopic remission was defined as a Mayo endoscopy subscore of 0 (NCT01903252)
Timeframe: Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 36 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 44 |
Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one. (NCT01903252)
Timeframe: Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 185 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 196 |
Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score (NCT01903252)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 193 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 205 |
Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score (NCT01903252)
Timeframe: Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 212 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 226 |
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS) (NCT01903252)
Timeframe: Week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended Induction | 53 |
A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0. (NCT01903252)
Timeframe: Week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended Induction | 183 |
Percentage of patients achieving the endpoint rectal bleeding sub-score of 0 (NCT01903252)
Timeframe: Week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended Induction | 146 |
Percentage of patients achieving the endpoint stool frequency sub-score of 0 (NCT01903252)
Timeframe: Week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended Induction | 64 |
Percentage of Patients Experiencing Complications related to UC (NCT01903252)
Timeframe: Week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended Induction | 0.0 |
Percentage of patients achieving an Urgency Score of 0. A score of 0 indicates no urgency reported in any of the three days prior to the visit at week 16. A score of 1 indicates urgency reported in any of the three days prior to the visits. (NCT01903252)
Timeframe: Week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended Induction | 109 |
Mayo Score of <= 2 points with no individual sub-score > 1 (NCT01903252)
Timeframe: Week 38
| Intervention | percentage of participants (Number) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 65.8 |
| 3.2/Day Maintenance Open-Label | 39.4 |
| 4.8g/Day Maintenance Open-Label | 29.6 |
Both has to be achieved, Clinical and Endoscopic Response which is defined by a decrease from baseline in the Mayo score of ≥ 3 points and > 30% of the baseline score, with an accompanying decrease in the rectal bleeding sub-score of ≥ 1 point or an absolute rectal bleeding sub-score of 0 or 1. (NCT01903252)
Timeframe: Week 38
| Intervention | percentage of participants (Number) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 89.6 |
| 3.2/Day Maintenance Open-Label | 78.1 |
| 4.8g/Day Maintenance Open-Label | 69.3 |
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS) (NCT01903252)
Timeframe: Week 38
| Intervention | percentage of participant (Number) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 70.3 |
| 3.2/Day Maintenance Open-Label | 33.9 |
| 4.8g/Day Maintenance Open-Label | 30.7 |
A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0. (NCT01903252)
Timeframe: Week 38
| Intervention | percentage of participants (Number) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 94.1 |
| 3.2/Day Maintenance Open-Label | 83.9 |
| 4.8g/Day Maintenance Open-Label | 78.4 |
Percentage of each dose group achieving an endoscopy sub score of 0 (NCT01903252)
Timeframe: Week 38
| Intervention | percentage of participants (Number) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 37.6 |
| 3.2/Day Maintenance Open-Label | 32.4 |
| 4.8g/Day Maintenance Open-Label | 13.6 |
Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one. (NCT01903252)
Timeframe: Week 38
| Intervention | percentage of participants (Number) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 73.8 |
| 3.2/Day Maintenance Open-Label | 58.8 |
| 4.8g/Day Maintenance Open-Label | 53.3 |
No urgency is a score of 0 and indicates that patients did not report urgency during any of the three days prior to the visit at week 38. A score of 1 indicates that urgency was reported during any of these three days. (NCT01903252)
Timeframe: Week 38
| Intervention | Participants (Count of Participants) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 161 |
| 3.2/Day Maintenance Open-Label | 173 |
| 4.8g/Day Maintenance Open-Label | 109 |
Percentage of each dose group achieving the endpoint rectal bleeding subscore 0 (NCT01903252)
Timeframe: Week 38
| Intervention | percentage of participants (Number) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 88.1 |
| 3.2/Day Maintenance Open-Label | 76.3 |
| 4.8g/Day Maintenance Open-Label | 74.9 |
Patients achieving a Stool Frequency sub-score of 0 (NCT01903252)
Timeframe: Week 38
| Intervention | Participants (Count of Participants) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 148 |
| 3.2/Day Maintenance Open-Label | 101 |
| 4.8g/Day Maintenance Open-Label | 66 |
Percentage of Patients with Complications related to UC (NCT01903252)
Timeframe: Week 38
| Intervention | Participants (Count of Participants) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 3 |
| 3.2/Day Maintenance Open-Label | 2 |
| 4.8g/Day Maintenance Open-Label | 1 |
Here is the count of participants with serious and non-serious adverse events assessed by the Division of Acquired Immune Deficiency Syndrome (AIDS) Table for Grading Adult Adverse Events for severity (mild/moderate/severe), expectedness (expected/unexpected), and relatedness to study drug (definitely, probably, possibly, unlikely, or unrelated). (NCT01295515)
Timeframe: Date consent signed to date off study, approximately 66 months and 2 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Interferon Treatment | 7 |
The outcome measure is the fold change in the ratio of HIV RNA to HIV DNA. For the pre and post interferon time point, the level of HIV RNA is divided by the level of HIV DNA and this ratio of the HIV RNA/DNA pre and post interferon is calculated to yield the fold change in HIV RNA/DNA levels. Fold change does not have units. (NCT01295515)
Timeframe: week 4 (post) and week 0 (pre)
| Intervention | fold change (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Patient #1 | Patient #2 | Patient #3 | Patient #4 | Patient #5 | Patient #6 | Patient #7 | |
| Interferon Treatment | 0.408 | 1.44 | 0.684 | 1.12 | 2.24 | 4.37 | 1.05 |
Cell associated HIV nucleic acid levels were measured using a single copy assay, and numbers of cells were quantified using a polymerase chain reaction method that detects C-C chemokine receptor type 5 (CCR5) DNA. (NCT01295515)
Timeframe: week 4 (post) compared to week 0 (pre)
| Intervention | # of copies of DNA/million cells (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient #1 HIV DNA Pre | Patient #1 HIV DNA Post | Patient #2 HIV DNA Pre | Patient #2 HIV DNA Post | Patient #3 HIV DNA Pre | Patient #3 HIV DNA Post | Patient #4 HIV DNA Pre | Patient #4 HIV DNA Post | Patient #5 HIV DNA Pre | Patient #5 HIV DNA Post | Patient #6 HIV DNA Pre | Patient #6 HIV DNA Post | Patient #7 HIV DNA Pre | Patient #7 HIV DNA Post | |
| Interferon Treatment | 1200 | 790 | 150 | 150 | 660 | 500 | 400 | 310 | 10 | 19 | 520 | 420 | 390 | 460 |
Cell associated HIV nucleic acid levels were measured using a single copy assay, and numbers of cells were quantified using a polymerase chain reaction method that detects RNA. (NCT01295515)
Timeframe: week 4 (post) compared to week 0 (pre)
| Intervention | # of copies of HIV RNA/million cells (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient #1 HIV RNA Pre | Patient #1 HIV RNA Post | Patient #2 HIV RNA Pre | Patient #2 HIV RNA Post | Patient #3 HIV RNA Pre | Patient #3 HIV RNA Post | Patient #4 HIV RNA Pre | Patient #4 HIV RNA Post | Patient #5 HIV RNA Pre | Patient #5 HIV RNA Post | Patient #6 HIV RNA Pre | Patient #6 HIV RNA Post | Patient #7 HIV RNA Pre | Patient #7 HIV RNA Post | |
| Interferon Treatment | 670 | 180 | 90 | 130 | 810 | 420 | 450 | 390 | 12 | 51 | 850 | 300 | 250 | 310 |
The outcome measure is copies of HIV RNA per ml of plasma. HIV RNA levels are measured using a polymerase chain reaction method. (NCT01295515)
Timeframe: week 4 (post) compared to week 0 (pre)
| Intervention | copies/ml (Median) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient #1 Pre | Patient #1 Post | Patient #2 Pre | Patient #2 Post | Patient #3 Pre | Patient #3 Post | Patient #4 Pre | Patient #4 Post | Patient #6 Pre | Patient #6 Post | Patient #7 Pre | Patient #7 Post | |
| Interferon Treatment | 0.7 | 3.8 | 0.2 | .02 | 3.8 | 0.8 | .02 | 1.5 | 1.3 | 0.36 | 9.1 | 8.8 |
Log(10) change in the percentage of activated T cells during the second 12 weeks of the study (NCT01090102)
Timeframe: Week 12, Week 24
| Intervention | Log10(percentage of T cells) (Mean) |
|---|---|
| Mesalamine Then Placebo | 0.003 |
| Placebo Then Mesalamine | -0.03 |
(NCT01090102)
Timeframe: Week 0, Week 12
| Intervention | Log10(percentage of T cells) (Mean) |
|---|---|
| Mesalamine Then Placebo | 0.03 |
| Placebo Then Mesalamine | -0.01 |
8 reviews available for mesalamine and Innate Inflammatory Response
| Article | Year |
|---|---|
Old but Fancy: Curcumin in Ulcerative Colitis-Current Overview.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Curcumin; Humans; Inflammation; Mesala | 2022 |
Ulcerative Colitis in Adults: A Review.
Topics: Adult; Antibodies, Monoclonal; Colitis, Ulcerative; Colorectal Neoplasms; Female; Humans; Inflammati | 2023 |
5-Aminosalicylic acid, a specific drug for ulcerative colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; Humans; Inflammation; | 2015 |
Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Dietary Fiber; Diverticulitis, Colon | 2016 |
Rheumatic manifestations of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Cadherins; Cytokines; Gastroenter | 2009 |
Risk of postoperative recurrence and postoperative management of Crohn's disease.
Topics: Anastomosis, Surgical; Anti-Bacterial Agents; Budesonide; Crohn Disease; Endoscopy; Gastroenterology | 2011 |
Effects of mesalazine on lamina propria white cell functions.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Antibody Formation; Aspirin; Clinical | 1995 |
[New forms of 5-aminosalicylate in inflammatory intestinal lesions].
Topics: Aminosalicylic Acids; Drug Combinations; Glucosamine; Humans; Inflammation; Intestinal Diseases; Mes | 1987 |
8 trials available for mesalamine and Innate Inflammatory Response
| Article | Year |
|---|---|
Efficacy of the Panax Notoginseng Ejiao Suppository in the Treatment of Patients with Ulcerative Proctitis and Its Effect on Inflammatory Response and Immune Function.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Gelatin; Humans; Immunity; Inflammatio | 2022 |
Effect of natural polyphenols (Pycnogenol) on oxidative stress markers in children suffering from Crohn's disease--a pilot study.
Topics: Adolescent; Amine Oxidase (Copper-Containing); Antioxidants; Biomarkers; Child; Crohn Disease; Femal | 2013 |
Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Colitis, Ulcerative; | 2013 |
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.
Topics: Biomarkers; Brachial Artery; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cross-Over Studies | 2014 |
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.
Topics: Biomarkers; Brachial Artery; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cross-Over Studies | 2014 |
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.
Topics: Biomarkers; Brachial Artery; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cross-Over Studies | 2014 |
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.
Topics: Biomarkers; Brachial Artery; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cross-Over Studies | 2014 |
Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; C-Reactive Protein; Colitis, Ulcerative; Cross-Over | 2015 |
Serum Fatty Acids Are Correlated with Inflammatory Cytokines in Ulcerative Colitis.
Topics: Adult; Aged; Colitis, Ulcerative; Colon; Cytokines; Fatty Acids, Unsaturated; Female; Humans; Inflam | 2016 |
Changes in immunohistochemical levels and subcellular localization after therapy and correlation and colocalization with CD68 suggest a pathogenetic role of Hsp60 in ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Bi | 2011 |
Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonic Pouches; Female; Humans | 2004 |
52 other studies available for mesalamine and Innate Inflammatory Response
| Article | Year |
|---|---|
Promoting mechanism of serum amyloid a family expression in mouse intestinal epithelial cells.
Topics: Animals; Colitis, Ulcerative; Epithelial Cells; Flagellin; Humans; Inflammation; Mesalamine; Mice; N | 2022 |
Qingchang Wenzhong Decoction reduce ulcerative colitis in mice by inhibiting Th17 lymphocyte differentiation.
Topics: Animals; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Inflammation; Interleu | 2022 |
Protective effect of 7-hydroxyl-1-methylindole-3-acetonitrile on the intestinal mucosal damage response to inflammation in mice with DSS-induced colitis.
Topics: Animals; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Drinking Wate | 2023 |
Use of Novel Biological Agent in Severe Ulcerative Colitis with Poor Response to Initial Therapy: A Case Report.
Topics: Adalimumab; Azathioprine; Biological Factors; Colitis, Ulcerative; Humans; Inflammation; Mesalamine | 2022 |
Mesalazine hollow suppositories based on 3D printing for treatment of ulcerative colitis.
Topics: Animals; Colitis, Ulcerative; Humans; Inflammation; Mesalamine; Printing, Three-Dimensional; Rats; S | 2023 |
5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis.
Topics: Animals; Anti-Inflammatory Agents; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Mod | 2023 |
Effect of Polycan, a β-Glucan from
Topics: Animals; beta-Glucans; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Dextrans; Disease Model | 2023 |
Dendrobium officinale polysaccharides alleviate colon tumorigenesis via restoring intestinal barrier function and enhancing anti-tumor immune response.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; CD8-Positive T-Lymphocytes; Colitis; Colon; Colorect | 2019 |
Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis.
Topics: Adult; Colitis, Ulcerative; Gastrointestinal Hemorrhage; Humans; Inflammation; Mesalamine; Patient R | 2020 |
Remission of ulcerative colitis flare-up induced by nivolumab.
Topics: Aged; Colitis, Ulcerative; Humans; Inflammation; Male; Mesalamine; Middle Aged; Nivolumab | 2020 |
The protective effect of Lactobacillus versus 5-aminosalicylic acid in ulcerative colitis model by modulation of gut microbiota and Nrf2/Ho-1 pathway.
Topics: Animals; Antioxidants; Colitis, Ulcerative; Escherichia coli; Fusobacterium; Gastrointestinal Microb | 2020 |
5-Aminosalicylic Acid Ameliorates Colitis and Checks Dysbiotic Escherichia coli Expansion by Activating PPAR-γ Signaling in the Intestinal Epithelium.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis; Colon; Cytochrome b Group; Dextran Sulfat | 2021 |
Comparison of anti-inflammatory activities of an anthocyanin-rich fraction from Portuguese blueberries (Vaccinium corymbosum L.) and 5-aminosalicylic acid in a TNBS-induced colitis rat model.
Topics: Animals; Anthocyanins; Anti-Inflammatory Agents; Antioxidants; Blueberry Plants; Colitis; Colon; Cyc | 2017 |
Oxidized 5-aminosalicylic acid activates Nrf2-HO-1 pathway by covalently binding to Keap1: Implication in anti-inflammatory actions of 5-aminosalicylic acid.
Topics: Animals; Anti-Inflammatory Agents; Colonic Neoplasms; HCT116 Cells; Heme Oxygenase-1; Humans; Hypoch | 2017 |
5-aminosalicylic acid improves lipid profile in mice fed a high-fat cholesterol diet through its dual effects on intestinal PPARγ and PPARα.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cholesterol, Dietary; Diet, High-Fat; Dyslipidemia | 2018 |
REDD1/Autophagy Pathway Is Associated with Neutrophil-Driven IL-1β Inflammatory Response in Active Ulcerative Colitis.
Topics: Adult; Autophagy; Colitis, Ulcerative; Colon; Crohn Disease; Extracellular Traps; Female; Humans; In | 2018 |
Mesalamine and azathioprine modulate junctional complexes and restore epithelial barrier function in intestinal inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis; Epithelial Cells; Inflammat | 2019 |
Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activity and therapeutic response.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biologica | 2019 |
Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; | 2014 |
Cyanidin-3-glucoside suppresses cytokine-induced inflammatory response in human intestinal cells: comparison with 5-aminosalicylic acid.
Topics: Anthocyanins; Anti-Inflammatory Agents; Cell Line; Cell Nucleus; Cell Survival; Cyclooxygenase 2; Cy | 2013 |
Are endoscopic endpoints reliable in therapeutic trials of ulcerative colitis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Endoscopy, Gastrointestinal; Follow-Up | 2013 |
DUOX2 and DUOXA2 form the predominant enzyme system capable of producing the reactive oxygen species H2O2 in active ulcerative colitis and are modulated by 5-aminosalicylic acid.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Cells, Cultured; Colitis, Ulcer | 2014 |
Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity.
Topics: Abdominal Pain; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Di | 2014 |
Immobilized immune complexes induce neutrophil extracellular trap release by human neutrophil granulocytes via FcγRIIIB and Mac-1.
Topics: Aminopyrine; Antigen-Antibody Complex; Antioxidants; Ascorbic Acid; Autoimmune Diseases; Butadienes; | 2014 |
5-Aminosalicylic acid attenuates allergen-induced airway inflammation and oxidative stress in asthma.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchoalveolar Lavage Fluid; Inflammation | 2014 |
Marine hydroquinone zonarol prevents inflammation and apoptosis in dextran sulfate sodium-induced mice ulcerative colitis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Apoptosis; Cell Line; Colitis, Ulcerative; | 2014 |
[Effect of qingchang huashi recipe on IL-17 in the plasma and colonic mucosa of patients with ulcerative colitis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drugs, Chinese Herbal; Humans; Immunol | 2014 |
Allicin alleviates inflammation of trinitrobenzenesulfonic acid-induced rats and suppresses P38 and JNK pathways in Caco-2 cells.
Topics: Animals; Caco-2 Cells; Disulfides; Humans; Inflammation; Interleukin-1beta; JNK Mitogen-Activated Pr | 2015 |
Combinatorial Intervention with Mesenchymal Stem Cells and Granulocyte Colony-Stimulating Factor in a Rat Model of Ulcerative Colitis.
Topics: Animals; Colitis, Ulcerative; Gene Expression Regulation; Granulocyte Colony-Stimulating Factor; Inf | 2015 |
PAK1 promotes intestinal tumor initiation.
Topics: Animals; Azoxymethane; beta Catenin; Carcinogenesis; Colonoscopy; Dextrans; Female; Gene Deletion; G | 2015 |
1,25-hydroxyvitamin D relieves colitis in rats via down-regulation of toll-like receptor 9 expression.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis; Disease Models, Animal; Down-Regulation; | 2015 |
Effects of Mesalazine on Morphological and Functional Changes in the Indomethacin-Induced Inflammatory Bowel Disease (Rat Model of Crohn's Disease).
Topics: Animals; Crohn Disease; Disease Models, Animal; Glucuronates; Indomethacin; Inflammation; Inflammato | 2017 |
Pattern of Inflammation on Surveillance Colonoscopy Does Not Predict Development of Colitis-associated Neoplasia.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Colitis, Ulcerative; Colonic N | 2016 |
5-Aminosalicylic acid inhibits inflammatory responses by suppressing JNK and p38 activity in murine macrophages.
Topics: Animals; Dose-Response Relationship, Drug; Inflammation; Interleukin-6; Macrophages; MAP Kinase Kina | 2017 |
Jianpi Qingchang decoction alleviates ulcerative colitis by inhibiting nuclear factor-κB activation.
Topics: Animals; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Drugs, Chinese Herbal; Inflammation; | 2017 |
Evaluation of fecal myeloperoxidase as a biomarker of disease activity and severity in ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Biopsy; Colitis, Ulcerative; Colonoscopy | 2012 |
Bioadhesive pellets increase local 5-aminosalicylic acid concentration in experimental colitis.
Topics: Animals; Anti-Inflammatory Agents; Biopolymers; Chitosan; Colitis; Colon; Drug Delivery Systems; Dru | 2012 |
Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Health Care Costs; Humans; Infl | 2012 |
Mucosal expression of basic fibroblastic growth factor, Syndecan 1 and tumor necrosis factor-alpha in diverticular disease of the colon: a case-control study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Case | 2012 |
Adjunct therapy of n-3 fatty acids to 5-ASA ameliorates inflammatory score and decreases NF-κB in rats with TNBS-induced colitis.
Topics: Animals; Colitis; Fatty Acids, Omega-3; Inflammation; Male; Mesalamine; NF-kappa B; PPAR gamma; Rats | 2013 |
Preventive therapy for complicated diverticular disease of the colon: looking for a correct therapeutic approach.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Diverticulitis, Colonic; Humans; | 2004 |
Free radical scavenging reactions of sulfasalazine, 5-aminosalicylic acid and sulfapyridine: mechanistic aspects and antioxidant activity.
Topics: Aminosalicylic Acids; Anions; Antioxidants; Electrons; Free Radical Scavengers; Free Radicals; Gluta | 2005 |
Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist.
Topics: Animals; Colitis; Colon; Gamma Rays; Gene Expression Regulation; Inflammation; Male; Mesalamine; PPA | 2008 |
L-glutamine enemas attenuate mucosal injury in experimental colitis.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis; Enema; Fatty Ac | 1999 |
Chemotactic properties of ICAM-1 and PECAM-1 on neutrophil granulocytes in ulcerative colitis: effects of prednisolone and mesalazine.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Cell Culture Techniques; Chemotax | 2000 |
Induction of colitis in rats by 2-2'-azobis(2-amidinopropane) dihydrochloride.
Topics: Amidines; Aminosalicylic Acids; Animals; Benzopyrans; Colitis; Inflammation; Intestinal Mucosa; Lipi | 1992 |
Neutrophil-mediated nitrosamine formation: role of nitric oxide in rats.
Topics: Aminosalicylic Acids; Animals; Chronic Disease; Colorectal Neoplasms; Inflammation; Male; Mesalamine | 1992 |
Inflammation in the rectal stump: the role of 5-amino salicylic acid suppositories.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Female; Humans; Inflammation; Male; Mesalamine; Po | 1990 |
Arachidonic acid metabolites and their role in inflammatory bowel disease. An update requiring addition of a pathway.
Topics: Aminosalicylic Acids; Arachidonic Acid; Arachidonic Acids; Biological Transport; Bradykinin; Colitis | 1985 |
[Ulcerative colitis. Activity index for the clinical and histological classification of inflammatory activity].
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Female; Humans; Inflammation; Male; Mesalamine; Pr | 1988 |
[Aminosalicylates and chronic inflammatory diseases of the digestive tract].
Topics: Aminosalicylic Acids; Chronic Disease; Humans; Inflammation; Intestinal Diseases; Mesalamine | 1987 |
Clinical efficacy of oral 5-aminosalicylic acid in the treatment of inflammatory bowel disease.
Topics: Administration, Oral; Aminosalicylic Acids; Humans; Inflammation; Intestinal Diseases; Mesalamine | 1985 |